Measuring quality of oral anticoagulation care: extending quality measurement to a new field. (Q37425137)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

review article

1 reference

title

Measuring quality of oral anticoagulation care: extending quality measurement to a new field (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

Adam J Rose

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Elaine M Hylek

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

1 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

Joint Commission Journal on Quality and Patient Safety

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

146-155

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Stroke Prevention in Atrial Fibrillation Study. Final results

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Canadian atrial fibrillation anticoaguiation (CAFA) study

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Risk factors for intracranial hemorrhage in outpatients taking warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Interactions of warfarin with drugs and food

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Medication use leading to emergency department visits for adverse drug events in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatran

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Validation of Clinical Classification Schemes for Predicting Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Measuring Quality of Care

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Pay for Performance in Commercial HMOs

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Pay for performance at the tipping point

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Pay for performance, version 2.0?

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Public reporting and pay for performance in hospital quality improvement

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Differences, disparities, and biases: clarifying racial variations in health care use.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Separate but not equal: the consequences of segregated health care.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Racial profiling: the unintended consequences of coronary artery bypass graft report cards

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Fighting unequal treatment: the Robert Wood Johnson Foundation and a quality-improvement approach to disparities

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Hospital nurse staffing and patient mortality, nurse burnout, and job dissatisfaction

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Hospital volume and surgical mortality in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Procedural volume as a marker of quality for CABG surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Prospective comparative study of computer programs used for management of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Computer control of anticoagulant dose for therapeutic management

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Computer assisted management of warfarin treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Quality indicators for the care of stroke and atrial fibrillation in vulnerable elders

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Quality indicators for medication use in vulnerable elders

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Assessing care of vulnerable elders: ACOVE project overview

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the P

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practices Committee. American Geriatric Society

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

A model for planning optimal follow-up for outpatients on warfarin anticoagulation. Warfarin Optimal Outpatient Follow-up Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Genetic determinants of response to warfarin during initial anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Warfarin dose management affects INR control.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Warfarin for atrial fibrillation in community-based practise

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Discrepancies in identification of major bleeding events in patients taking warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Comparison of weighted performance measurement and dichotomous thresholds for glycemic control in the Veterans Health Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Measuring quality of care in patients with multiple clinical conditions: summary of a conference conducted by the Society of General Internal Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Quality of care is associated with survival in vulnerable older patients

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

The quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Acove quality indicators

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Assessing care of vulnerable elders: methods for developing quality indicators

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Potential pitfalls of disease-specific guidelines for patients with multiple conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Racial disparities in the filling of warfarin prescriptions for nonvalvular atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

Quality of anticoagulation control: do race and language matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

African American race was associated with an increased risk of complications following venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2809%2935019-9

7 January 2021

10.1016/S1553-7250(09)35019-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19326806%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference